Cardiol Therapeutics Inc Class A has seen a notable uptick in its stock performance this week, driven by several key developments in its clinical programs.
Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a positive shift in its stock price, reflecting a 1.85% increase in one day and a 6.59% rise over the past week. This follows a significant 56.25% gain over the last month and an impressive 102.21% year-to-date performance. The company's recent operational updates and financing activities have contributed to this bullish sentiment among investors.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$315.42M
52W high
$3.15
52W low
$1.23
1W change
+6.59%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 118.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+118.2% Upside
Current Price
C$2.75
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
68.4%
Annualized
90-Day Vol
55.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.92 | C$2.31 – C$3.70 |
| 60 trading days | C$3.10 | C$2.22 – C$4.32 |
| 90 trading days | C$3.29 | C$2.18 – C$4.95 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: For Canadian retail investors, Cardiol Therapeutics appears to be on a growth trajectory, supported by its clinical advancements and financial maneuvers. However, potential investors should consider the inherent risks associated with biotechnology stocks.
Cardiol Therapeutics Inc Class A Stock Gains 6.59% This Week
With a market cap of C$315.42 million and a 52-week price range of C$1.23 to C$3.15, Cardiol Therapeutics has seen substantial volatility, which reflects both the excitement and risks in the biotech sector.
Bull case
The positive outlook for Cardiol Therapeutics is strengthened by the start of the Phase III MAVERIC trial for its lead product, CardiolRx™, designed to treat recurrent pericarditis. Encouraging results from earlier trials and the recent U.S. patent approval for CardiolRx™ and CRD-38 further enhance its market position and potential revenue streams.
Bear case
Despite these promising developments, investors should remain cautious. Cardiol Therapeutics is currently operating at a loss, with a negative return on equity of -190.2%. The company's financial health, indicated by a profit margin of 0.0%, raises concerns about its sustainability and ability to fund its clinical programs without further dilution.
Recent Price Action
Cardiol Therapeutics Inc Class A (CRDL.TO) has gained 1.85% in the last trading session, closing at C$3.03. Over the past week, the stock has risen by 6.59%, reflecting investor optimism following several key announcements from the company.
Catalysts Behind the Move
Advertisement
The recent surge in Cardiol Therapeutics' stock price can be attributed to multiple factors. The company announced the initiation of the Phase III MAVERIC trial for CardiolRx™, which aims to address recurrent pericarditis. Additionally, the completion of a bought deal financing raised C$14.85 million, enhancing the company's financial position to support ongoing clinical trials. Furthermore, the grant of a U.S. patent for CardiolRx™ and CRD-38 covering a range of cardiac disorders has fortified its market potential.
Technical Picture
From a technical standpoint, Cardiol Therapeutics' stock is currently trading above its 50-day moving average of C$1.88 and its 200-day moving average of C$1.63, indicating bullish momentum. The stock has a beta of 0.47, suggesting lower volatility compared to the broader market. The current trading volume of 342,920 shares is slightly above the 20-day average volume of 262,190 shares, reflecting increased investor interest.
Insider Activity
No recent insider activity has been reported, but the company's strong performance and operational updates may attract interest from insiders moving forward.
Conclusion
As of the last close, Cardiol Therapeutics Inc Class A is trading at C$3.03, reflecting a 1D increase of 1.85%. Investors should remain aware of the company's ongoing developments and the inherent risks associated with biotech investments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
